On October 18, 2022, Shenzhen Beike Biotechnology Co., Ltd. held an appointment ceremony and academic report for external expert consultants. Dr. Hu Junyuan, chairman of Beike Biotechnology, issued an external expert consultant certificate to Professor Wang Zhihua of the State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences. Professor Wang Zhihua officially became an external expert of Beike Biotech through signing the contract, which injected strong impetus into the development of Beike Biotech.
It is reported that Beike Biotechnology and Professor Wang Zhihua successfully reached an intention to cooperate on a project,The two parties will cooperate on projects such as the clinical application development of exosomes and the clinical treatment of stem cells in cardiac diseases and aging-related diseases, and jointly commit to research to improve human health.
At the signing ceremony, Dr. Hu Junyuan, chairman of Beike Biotech, said that talents are the backbone of enterprise development, and the signing of the contract with Professor Wang Zhihua is a very important link in the construction and development of Beike Biotech’s high-quality talent team. As a high-tech enterprise in the biomedical industry, Beike Biotech has been diligent and steady in carrying out technology research and development innovation. It has gradually built multiple technology research and development platforms and cultivated a team with strong research and development capabilities. With the gradual opening up of national policies, competition in the external environment has become increasingly fierce.In the future, Beike Biotech will continue to increase investment in R&D, stabilize the R&D team, introduce high-tech talents, and cooperate with more outstanding scientist teams. It must not only deepen technological research and development, but also undertake the important mission of transformation and promotion of results, open up the future technology engine of cutting-edge medicine, and improve people’s health.
Professor Wang Zhihua
Professor Wang Zhihua is currently a researcher/doctoral supervisor at the State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, a researcher at Shenzhen Hospital, Fuwai Hospital, Chinese Academy of Medical Sciences, and a recipient of the National Natural Science Foundation of China Outstanding Youth Fund. The main research directions are pathological cardiac hypertrophy and cardiac aging, analyzing the molecular mechanisms of pathological growth and aging of cardiomyocytes from different dimensions such as epigenetics, gene transcription, protein translation, and metabolic networks, and conducting drug development and translational research. He serves as a director of the Chinese Youth Science and Technology Workers Association, a member of the Circulatory Physiology Committee of the Chinese Physiological Society, a member of the Cardiovascular Youth Committee of the Chinese Pathophysiology Society, and deputy editor-in-chief of the journal Front Cardiovasc Med. He is authorized to hold 5 national invention patents. He presides over scientific research projects such as the National Natural Science Foundation of China’s General/Excellent Youth Project, the Guangdong Provincial Fund Committee’s General Project, and the Shenzhen Science and Technology Innovation Committee’s Outstanding Youth Project. He has worked in Nature Medicine, Circulation, Circulation Research, Hypertension, and Front Cell Dev. Published 40 research papers in professional journals such as Biol; participated in the editing of monographs such as Epigenetics Methods, “Basics and Clinical Practice of Cardiovascular Physiology”, “Chinese Medical Encyclopedia”, and hosted the special issue of Epigenetic Regulations in Cardiovascular Diseases.